We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Carsten
Flohr
carsten.flohr@kcl.ac.uk
Tom
Ewen
tom.ewen@newcastle.ac.uk
Tom
Ewen
tom.ewen@ncl.ac.uk
Prof
Carsten
Flohr
carsten.flohr@kcl.ac.uk
Dermatitis and eczema
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The purpose of the research is to collect information from adult and children with eczema, starting certain treatments,
referred to as ‘systemic immuno-modulators’. As eczema is often a long-term condition, it is important to establish
how well these medicines work with regard to improvement in disease severity, quality of life and also safety,
especially when these are used for longer periods of time.
All medicines prescribed for eczema in clinics have already undergone careful testing in clinical trials, however, the
picture we get from clinical trials is not complete. This project intends to fill this gap in knowledge and collect
information on patients treated with systemic immuno-modulators attending regular dermatology clinics. Patients who
have other health problems but nevertheless start one of these medications will also be included, making the results
more representative of the “real world” use of these medicines. Rates of medical side effects will be compared
between medications, and the results will then be used to provide clinicians and patients with a better picture of any
potential increased risk of these therapies.
Additionally, this study will look into the ‘real life’ cost of treating eczema, examining how much these therapies cost in
the long term, compared to how well they work.
As part of this study, we also intend to set up a Biorepository, where patients will be asked to provide optional blood
and skin samples to help us better understand how eczema develops and why some therapies work better in some
people, or cause more side effects in others. This is a fully optional section of the research.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
1. Insufficient understanding of the study by the patient and/or parent/guardian. 2. Patients who are currently participating in a randomised clinical trial.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Tom
Ewen
tom.ewen@newcastle.ac.uk
Prof
Carsten
Flohr
carsten.flohr@kcl.ac.uk
Tom
Ewen
tom.ewen@ncl.ac.uk
Prof
Carsten
Flohr
carsten.flohr@kcl.ac.uk
The study is sponsored by GUY'S AND ST THOMAS' NHS FOUNDATION TRUST and funded by THE BRITISH SKIN FOUNDATION .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 43501
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
